Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.

Theelen WSME, Kuilman T, Schulze K, Zou W, Krijgsman O, Peters DDGC, Cornelissen S, Monkhorst K, Sarma P, Sumiyoshi T, Amler LC, Willems SM, Blaauwgeers JLG, van Noesel CJM, Peeper DS, van den Heuvel MM, Kowanetz M.

PLoS One. 2019 May 24;14(5):e0216864. doi: 10.1371/journal.pone.0216864. eCollection 2019.


Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.

Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L.

Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9.


Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.

Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R, Schleifman EB, Motlhabi M, French D, Wong CV, Peters E, Molinero L, Raja R, Amler LC, Hampton GM, Lackner MR, Kabbarah O.

PLoS One. 2016 Nov 15;11(11):e0165856. doi: 10.1371/journal.pone.0165856. eCollection 2016.


Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, Amler LC, Hampton GM, Johnston S, Krop I, Schmid P, Lackner MR.

Nat Commun. 2016 May 13;7:11579. doi: 10.1038/ncomms11579.


Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.


Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.

Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, Fu L, Amler LC, Bais C, Wang Y.

Clin Cancer Res. 2015 Jul 1;21(13):2941-51. doi: 10.1158/1078-0432.CCR-14-3111. Epub 2015 Apr 2.


Discovery and development of DNA methylation-based biomarkers for lung cancer.

Walter K, Holcomb T, Januario T, Yauch RL, Du P, Bourgon R, Seshagiri S, Amler LC, Hampton GM, S Shames D.

Epigenomics. 2014 Feb;6(1):59-72. doi: 10.2217/epi.13.81.


High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y.

Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26.


High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, Do A, Fu L, Xiao Y, Raja R, Jiang B, Malekafzali A, Stern H, Settleman J, Wilson TR, Hampton GM, Yauch RL, Pirzkall A, Amler LC.

PLoS One. 2013;8(2):e56765. doi: 10.1371/journal.pone.0056765. Epub 2013 Feb 28. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/63f57c72-c869-4ef5-94d1-3cbd6c2e3678. AnDo [corrected to Do, An].


Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM.

Cancer Res. 2013 Jan 15;73(2):824-33. doi: 10.1158/0008-5472.CAN-12-1611. Epub 2012 Nov 20.


Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.


Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Rocha Lima CM, Bayraktar S, Flores AM, MacIntyre J, Montero A, Baranda JC, Wallmark J, Portera C, Raja R, Stern H, Royer-Joo S, Amler LC.

Cancer Invest. 2012 Dec;30(10):727-31. doi: 10.3109/07357907.2012.732163. Epub 2012 Oct 12.


Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.


ERK inhibition overcomes acquired resistance to MEK inhibitors.

Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.

Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8.


DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.

Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, Iniguez L, Soriano R, Huw L, Stern H, Modrusan Z, Seshagiri S, Hampton GM, Amler LC, Bourgon R, Yauch RL, Shames DS.

Clin Cancer Res. 2012 Apr 15;18(8):2360-73. doi: 10.1158/1078-0432.CCR-11-2635-T. Epub 2012 Jan 19.


Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.


Molecular biomarker analyses using circulating tumor cells.

Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR.

PLoS One. 2010 Sep 8;5(9):e12517. doi: 10.1371/journal.pone.0012517.


HER3 mRNA as a predictive biomarker in anticancer therapy.

Amler LC.

Expert Opin Biol Ther. 2010 Sep;10(9):1343-55. doi: 10.1517/14712598.2010.512003. Review.


Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR.

Clin Cancer Res. 2010 Jul 15;16(14):3670-83. doi: 10.1158/1078-0432.CCR-09-2828. Epub 2010 May 7. Erratum in: Clin Cancer Res. 2011 Apr 1;17(7):2066-7.


Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U.

J Clin Oncol. 2010 Mar 1;28(7):1215-23. doi: 10.1200/JCO.2009.22.3354. Epub 2009 Nov 9.


Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.

Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, Lewis Phillips GD, Luis E, Cavet G, Hu X, Amler LC, Lackner MR.

Mol Cancer Ther. 2009 Aug;8(8):2110-21. doi: 10.1158/1535-7163.MCT-09-0381. Epub 2009 Aug 11.


Genetic alterations and oncogenic pathways associated with breast cancer subtypes.

Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, Chant J, Stokoe D, Lackner MR, Cavet G.

Mol Cancer Res. 2009 Apr;7(4):511-22. doi: 10.1158/1541-7786.MCR-08-0107.


Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, Toy K, Rivers CS, Modrusan Z, Amler LC, Lackner MR.

Cancer Res. 2008 Jul 1;68(13):5380-9. doi: 10.1158/0008-5472.CAN-08-0234.


Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.

Amler LC, Goddard AD, Hillan KJ.

Cold Spring Harb Symp Quant Biol. 2005;70:483-8. Review.


Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98.


Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ.

J Clin Oncol. 2005 Sep 1;23(25):5900-9. Epub 2005 Jul 25.


Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.

Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM.

Cancer Res. 2000 Nov 1;60(21):6134-41.


Identification and characterization of novel genes located at the t(1;15)(p36.2;q24) translocation breakpoint in the neuroblastoma cell line NGP.

Amler LC, Bauer A, Corvi R, Dihlmann S, Praml C, Cavenee WK, Schwab M, Hampton GM.

Genomics. 2000 Mar 1;64(2):195-202.


Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa.

Praml C, Amler LC, Dihlmann S, Finke LH, Schlag P, Schwab M.

Oncogene. 1998 Oct 15;17(15):2009-12.


Genomic instability in 1p and human malignancies.

Schwab M, Praml C, Amler LC.

Genes Chromosomes Cancer. 1996 Aug;16(4):211-29. Review.


The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma.

Amler LC, Schürmann J, Schwab M.

Genes Chromosomes Cancer. 1996 Feb;15(2):134-7.


Human homologue of a candidate for the Mom1 locus, the secretory type II phospholipase A2 (PLA2S-II), maps to 1p35-36.1/D1S199.

Praml C, Savelyeva L, Le Paslier D, Siracusa LD, Buchberg AM, Schwab M, Amler LC.

Cancer Res. 1995 Dec 1;55(23):5504-6.


The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.

Gehring M, Berthold F, Edler L, Schwab M, Amler LC.

Cancer Res. 1995 Nov 15;55(22):5366-9.


A reciprocal translocation (1;15) (36.2;q24) in a neuroblastoma cell line is accompanied by DNA duplication and may signal the site of a putative tumor suppressor-gene.

Amler LC, Corvi R, Praml C, Savelyeva L, Le Paslier D, Schwab M.

Oncogene. 1995 Mar 16;10(6):1095-101. Erratum in: Oncogene 1995 Dec 7;11(11):2453.


Reciprocal translocation at 1p36.2/D1S160 in a neuroblastoma cell line: isolation of a YAC clone at the break.

Amler LC, Corvi R, Praml C, Savelyeva L, Le Paslier D, Schwab M.

Eur J Cancer. 1995;31A(4):527-30.


MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells.

Corvi R, Amler LC, Savelyeva L, Gehring M, Schwab M.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5523-7.


Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer.

Schwab M, Amler LC.

Genes Chromosomes Cancer. 1990 Jan;1(3):181-93. Review.


Neuroblastoma consensus deletion maps to 1p36.1-2.

Weith A, Martinsson T, Cziepluch C, Brüderlein S, Amler LC, Berthold F, Schwab M.

Genes Chromosomes Cancer. 1989 Nov;1(2):159-66.


Supplemental Content

Loading ...
Support Center